Literature DB >> 20101427

Venous thromboembolism in southern Chinese patients with systemic lupus erythematosus.

Chi Chiu Mok1, Ling Yin Ho, Ka Lung Yu, Chi Hung To.   

Abstract

The objective is to study the annual incidence and standardized incidence ratio (SIR) of venous thromboembolism (VTE) in a cohort of Chinese patients with systemic lupus erythematosus (SLE). VTE events of SLE patients occurring between 1999 and 2008 were identified from our database, and the annual incidence of VTE was calculated according to the cohort size. SIRs were estimated by the ratios of the incidence of VTE in SLE to the general population. In 2008, 516 SLE patients were in our cohort. The mean age of SLE onset was 32.2 +/- 14 years and the duration of SLE was 9.3 +/- 8.8 years. Fifty-seven percent of the patients had disease duration of > or =5 years. Between 1999 and 2008, 18 episodes of VTE occurred in 14 patients. The incidence of VTE did not show significant fluctuation and the mean annual incidence was 4.2/1,000 patient-year. The reported VTE events were: popliteal vein thrombosis (56%), pulmonary embolism (22%), renal vein, retinal vein, subclavian vein and dural sinus thrombosis (5.6% each). The cumulative risks of VTE since SLE diagnosis were 2.8% and 3.7% at 5 and 10 years, respectively. Compared to the general population, the mean SIR of VTE in SLE patients within this period was 11.9 (7.31-19.6; p < 0.001). The SIR of VTE was highest in patients under the age of 30 years. The presence of the antiphospholipid antibody was independently associated with VTE (HR 4.36 [1.67-11.4]; p = 0.003). Although venous thrombosis is uncommon in Chinese, Chinese patients with SLE are 12 times more prone to VTE than the general population.

Entities:  

Mesh:

Year:  2010        PMID: 20101427     DOI: 10.1007/s10067-009-1364-z

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  17 in total

1.  Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus.

Authors:  Emily Somers; Laurence S Magder; Michelle Petri
Journal:  J Rheumatol       Date:  2002-12       Impact factor: 4.666

2.  Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study.

Authors:  S Manzi; E N Meilahn; J E Rairie; C G Conte; T A Medsger; L Jansen-McWilliams; R B D'Agostino; L H Kuller
Journal:  Am J Epidemiol       Date:  1997-03-01       Impact factor: 4.897

3.  Detection of anti-annexin IV and V antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus.

Authors:  A Satoh; K Suzuki; E Takayama; K Kojima; T Hidaka; M Kawakami; I Matsumoto; F Ohsuzu
Journal:  J Rheumatol       Date:  1999-08       Impact factor: 4.666

4.  Incidence and risk factors of thromboembolism in systemic lupus erythematosus: a comparison of three ethnic groups.

Authors:  Chi Chiu Mok; Sandy Shuk Kuen Tang; Chi Hung To; Michelle Petri
Journal:  Arthritis Rheum       Date:  2005-09

5.  Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXV. Smoking, older age, disease activity, lupus anticoagulant, and glucocorticoid dose as risk factors for the occurrence of venous thrombosis in lupus patients.

Authors:  Jaime Calvo-Alén; Sergio M A Toloza; Mónica Fernández; Holly M Bastian; Barri J Fessler; Jeffrey M Roseman; Gerald McGwin; Luis M Vilá; John D Reveille; Graciela S Alarcón
Journal:  Arthritis Rheum       Date:  2005-07

6.  Antibodies directed to protein S in patients with systemic lupus erythematosus: prevalence and clinical significance.

Authors:  Maria Laura Bertolaccini; Giovanni Sanna; Shvaita Ralhan; Laura C Gennari; Joan T Merrill; Munther A Khamashta; Graham R V Hughes
Journal:  Thromb Haemost       Date:  2003-10       Impact factor: 5.249

7.  Thromboembolism in paediatric lupus patients.

Authors:  D M Levy; M P Massicotte; E Harvey; D Hebert; E D Silverman
Journal:  Lupus       Date:  2003       Impact factor: 2.911

8.  Acquired activated protein C resistance is associated with the co-existence of anti-prothrombin antibodies and lupus anticoagulant activity in patients with systemic lupus erythematosus.

Authors:  Junzo Nojima; Hirohiko Kuratsune; Etsuji Suehisa; Tomio Kawasaki; Takashi Machii; Teruo Kitani; Yoshinori Iwatani; Yuzuru Kanakura
Journal:  Br J Haematol       Date:  2002-08       Impact factor: 6.998

9.  The contribution of inherited and acquired thrombophilic defects, alone or combined with antiphospholipid antibodies, to venous and arterial thromboembolism in patients with systemic lupus erythematosus.

Authors:  Jan-Leendert P Brouwer; Marc Bijl; Nic J G M Veeger; Hanneke C Kluin-Nelemans; Jan van der Meer
Journal:  Blood       Date:  2004-03-16       Impact factor: 22.113

10.  Pulmonary thromboembolism in Asians/Pacific Islanders in the United States: analysis of data from the National Hospital Discharge Survey and the United States Bureau of the Census.

Authors:  Paul D Stein; Fadi Kayali; Ronald E Olson; Creagh E Milford
Journal:  Am J Med       Date:  2004-04-01       Impact factor: 4.965

View more
  8 in total

1.  Anti-RNP/Sm antibodies in patients with systemic lupus erythematosus and its role in thrombosis: a case-control study.

Authors:  María Del Carmen Zamora-Medina; Andrea Hinojosa-Azaola; Carlos A Nuñez-Alvarez; Angel Gabriel Vargas-Ruiz; Juanita Romero-Diaz
Journal:  Clin Rheumatol       Date:  2018-12-04       Impact factor: 2.980

2.  Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees.

Authors:  Hussain R Yusuf; W Craig Hooper; Scott D Grosse; Christopher S Parker; Sheree L Boulet; Thomas L Ortel
Journal:  Thromb Res       Date:  2014-10-22       Impact factor: 3.944

Review 3.  Postoperative risk of venous thromboembolism in rheumatic disease patients.

Authors:  Lauren E Wong; Anne R Bass
Journal:  Curr Rheumatol Rep       Date:  2015-02       Impact factor: 4.592

4.  Risk of venous thromboembolism among hospitalizations of adults with selected autoimmune diseases.

Authors:  Hussain R Yusuf; W Craig Hooper; Michele G Beckman; Qing C Zhang; James Tsai; Thomas L Ortel
Journal:  J Thromb Thrombolysis       Date:  2014-10       Impact factor: 2.300

5.  The risk of pulmonary embolism and deep venous thrombosis in systemic lupus erythematosus: A general population-based study.

Authors:  J Antonio Aviña-Zubieta; Kateryna Vostretsova; Mary A De Vera; Eric C Sayre; Hyon K Choi
Journal:  Semin Arthritis Rheum       Date:  2015-05-19       Impact factor: 5.532

6.  Brief Report: Single-nucleotide polymorphisms in VKORC1 are risk factors for systemic lupus erythematosus in Asians.

Authors:  Rachel Kaiser; Kimberly E Taylor; Yun Deng; Jian Zhao; Yonghong Li; Joanne Nititham; Monica Chang; Joseph Catanese; Ann B Begovich; Elizabeth E Brown; Jeffrey C Edberg; Gerald McGwin; Graciela S Alarcón; Rosalind Ramsey-Goldman; John D Reveille; Luis M Vila; Michelle Petri; Robert P Kimberly; Xuebing Feng; Lingyun Sun; Nan Shen; Wei Li; Jian-Xin Lu; Edward K Wakeland; Quan-Zhen Li; Wanling Yang; Yu-Lung Lau; Fei-Lan Liu; Deh-Ming Chang; Chack-Yung Yu; Yeong W Song; Betty P Tsao; Lindsey A Criswell
Journal:  Arthritis Rheum       Date:  2013-01

7.  Systemic Lupus Erythematosus Is Associated With a High Risk of Venous Thromboembolism in Hospitalized Patients Leading to Poor Outcomes and a Higher Cost: Results From Nationwide Inpatient Sample Database 2003-2011.

Authors:  Shweta Kishore; Shraddha Jatwani; Bharat Malhotra; Seth T Lirette; Varun Mittal; Vikas Majithia
Journal:  ACR Open Rheumatol       Date:  2019-05-13

8.  Practical Utility of D-dimer Test for Venous Thromboembolism in Systemic Lupus Erythematosus Depends on Disease Activity: a Retrospective Cohort Study.

Authors:  Yoon Jeong Oh; Eun Hye Park; Jun Won Park; Yeong Wook Song; Eun Bong Lee
Journal:  J Korean Med Sci       Date:  2020-11-09       Impact factor: 2.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.